Sobi Set To Grow Hematology Franchise With $1.7bn CTI Biopharma Buy

Deal Prices Target Company At Big Premium

Sobi plans to capitalize on the complimentary expertise at CTI Biopharma to together boost sales of the latter firm’s myelofibrosis drug Vonjo and enhance the Swedish pharma firm’s overall growth.

Merger and Acquisitions, partnership or work together
Sobi will merge CTI's Vonjo into its growing hematology franchise • Source: Shutterstock

Swedish Orphan Biovitrum AB (Sobi) said on 10 May that it will pay $1.7bn to acquire CTI BioPharma Corp., buying an immediate source of revenue growth in the form of CTI’s Vonjo (pacritinib), approved in the US last year to treat myelofibrosis patients with severe thrombocytopenia. The product will also help Sobi grow its overall revenue by adding to its hematology business, already its top-selling franchise.

Sobi president and CEO Guido Oelkers said during a same-day call with analysts and investors that Vonjo represents a “significant...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.